AGM
AVIR icon

Alpine Global Management’s Atea Pharmaceuticals AVIR Stock Holding History

Alpine Global Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,858
Closed -$52K – 170
2022
Q4 		$52K Buy
+10,858
New +$54.9K 0.02% 401

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alpine Global Management's AVIR Position: Q1 2023 in Review

Alpine Global Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 10,858 shares — an estimated $52K sold.

Alpine Global Management first reported a position in AVIR in Q4 2022 and held it in 1 quarter. The position peaked at $52K in Q4 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Alpine Global Management reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 10,858 Atea Pharmaceuticals shares in Q1 2023, an estimated $52K.
  • Alpine Global Management first reported a position in Atea Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Atea Pharmaceuticals position peaked at $52K in Q4 2022.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.